AGTX Agentix Corp.
Distress ·
Agentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.
We have not published a story on Agentix yet. When there is news, it will appear here.
Agentix Corp. is a clinical development stage company focused on developing and commercializing novel therapeutics for metabolic disease. Its principal business objective is to develop two assets designed to be peripherally restricted, meaning they do not cross the blood brain barrier. Both target the peripheral CB1 receptor, which is involved in regulating glucose and lipid metabolism, for conditions including obesity, type 2 diabetes and nonalcoholic fatty liver disease. The company has not yet generated or realized meaningful revenues. Its lead candidate, AGTX-2004, is a peripherally-acting CB1 receptor antagonist. Its IND application was cleared by the FDA, and the company is preparing a Phase 1 safety and tolerability study in humans, to be managed by its Australian subsidiary, Agentix Australia Pty Ltd. The company licensed AGTX-2004 worldwide from Taiwan's National Health Research Institutes in March 2021. Its second asset, AGTX-2003, is in additional enabling animal studies ahead of an IND filing. The company plans to partner with larger biopharma players for the pivotal stages of commercialization.
| Product or program | What it is | Stage |
|---|---|---|
| AGTX-2004 (DBPR211) | Peripherally-acting CB1 receptor antagonist for obesity and type 2 diabetes | IND cleared by the FDA; preparing Phase 1 |
| AGTX-2003 (RTI-1092769) | Peripherally-acting CB1 receptor inverse agonist for obesity and NAFLD | enabling animal studies ahead of IND filing |
Agentix Corp. trades under the ticker AGTX on OTC.
Agentix Corp. is listed on OTC.
The SEC Central Index Key (CIK) for Agentix Corp. is 1603345. Its filings are on SEC EDGAR.
40,066,951 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Agentix Corp. under United States.
Our directory classifies Agentix Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Agentix Corp. is US00848A1034.
aibio.space lists Agentix Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Agentix Corp. is a clinical development stage company focused on developing and commercializing novel therapeutics for metabolic disease. Its principal business objective is to develop two assets designed to be peripherally restricted, meaning they do not cross the blood brain barrier.
AGTX-2004 (DBPR211): Peripherally-acting CB1 receptor antagonist for obesity and type 2 diabetes Stage: IND cleared by the FDA; preparing Phase 1.
AGTX-2003 (RTI-1092769): Peripherally-acting CB1 receptor inverse agonist for obesity and NAFLD Stage: enabling animal studies ahead of IND filing.
Agentix Corp. reported a net loss of $485,636 for the fiscal year ended Mar 31, 2026, and used $108,529 of cash in operations, per its annual report to the SEC.
$125,079 in the fiscal year ended Mar 31, 2026, per its annual report.
$38 in cash at Jun 30, 2026, per its 10-Q.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio